(Q36902286)

17 August 2017

1 reference

title

Systemic and acquired immune responses in Alzheimer's disease (English)

1 reference

17 August 2017

2

Tony Wyss-Coray

1 reference

17 August 2017

Markus Britschgi

1

1 reference

PubMed ID

17678963

17 August 2017

language of work or name

1 reference

1 January 2007

1 reference

International Review of Neurobiology

17 August 2017

1 reference

17 August 2017

82

1 reference

17 August 2017

205-233

1 reference

Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factorin situ

17 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Inflammation and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. Results of a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Blood to brain transport of interleukin links the immune and central nervous systems

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Reversible association of the cytokines MIP-1 alpha and MIP-1 beta with the endothelia of the blood-brain barrier.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Bidirectional transport of interleukin-1 alpha across the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Blood-borne interleukin-1 alpha is transported across the endothelial blood-spinal cord barrier of mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Penetration of interleukin-6 across the murine blood-brain barrier

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

1 reference

7 January 2021

Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

A High Plasma Concentration of TNF- Is Associated With Dementia in Centenarians

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

The role of complement and complement receptors in induction and regulation of immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Chemokines and pro-inflammatory cytokines in Down's syndrome: an early marker for Alzheimer-type dementia?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Radiation-induced astrocytic and microglial responses in mouse brain

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

The role of neuronal growth factors in neurodegenerative disorders of the human brain

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Brain-derived neurotrophic factor is reduced in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Genetics. Was the Human Genome Project worth the effort?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Evidence linking neuronal cell death to autoimmunity in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Twenty years of research on cytokine-induced sickness behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Decrease of TGF-beta1 plasma levels and increase of nitric oxide synthase activity in leukocytes as potential biomarkers of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Anti-NGF autoantibodies and NGF in sera of Alzheimer patients and in normal subjects in relation to age.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Reduced levels of amyloid beta-peptide antibody in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Molecular profile of reactive astrocytes--implications for their role in neurologic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

The role of complement in Alzheimer's disease pathology

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Abeta-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Altered expression of transforming growth factor-beta in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Neuronal localization of C1q in preclinical Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Complement components of the innate immune system in health and disease in the CNS.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Cerebrovascular transforming growth factor-beta contributes to inflammation in the Alzheimer's disease brain

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Increased soluble tumor necrosis factor receptor levels in the serum of elderly people.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Complement association with neurons and beta-amyloid deposition in the brains of aged individuals with Down Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Decreased trkA neurotrophin receptor expression in the parietal cortex of patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Region-Specific Neurotrophin Imbalances in Alzheimer Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Proteome-based plasma biomarkers for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Autoantibodies to amyloid-beta and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer's disease brain tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Amyloid β protein deposition and neuron loss in osteopetrotic (op/op) mice

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Gene expression profile analysis of lymphocytes from Alzheimer's patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Different mechanisms influencing permeation of PDGF-AA and PDGF-BB across the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Circulating TGF-beta1 does not cross the intact blood-brain barrier.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Oncostatin M and the interleukin-6 and soluble interleukin-6 receptor complex regulate alpha1-antichymotrypsin expression in human cortical astrocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Microglial cell population dynamics in the injured adult central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor rece

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Stage-dependent BDNF serum concentrations in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

T cells infiltrate the brain in murine and human transmissible spongiform encephalopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Early complement activation increases in the brain in some aged normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Inflammatory markers in younger vs elderly normal volunteers and in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Increased production of inflammatory cytokines in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Relationship of interleukin-1 beta and beta 2-microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Increased cerebrospinal fluid fas (Apo-1) levels in Alzheimer's disease. Relationship with IL-6 concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

PDGF is associated with neuronal and glial alterations of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Inflammation of the brain in Alzheimer's disease: implications for therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Anti-inflammatory drugs and Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Chemokines and chemokine receptors in the CNS: a possible role in neuroinflammation and patterning

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

NGF level of is not decreased in the serum, brain-spinal fluid, hippocampus, or parietal cortex of individuals with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Neurotrophin-3 (NT-3) levels in the developing rat nervous system and in human samples.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Proinflammatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild-moderate Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

TNFalpha transport across the blood-brain barrier is abolished in receptor knockout mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Why study transport of peptides and proteins at the neurovascular interface

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Transport of brain-derived neurotrophic factor across the blood-brain barrier.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Permeability of the blood-brain barrier to neurotrophins.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

The impact of systemic infection on the progression of neurodegenerative disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

The decrease of CD8-positive lymphocytes in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Three or more routes for leukocyte migration into the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Chemokines, mononuclear cells and the nervous system: heaven (or hell) is in the details.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Decline of immune responsiveness: a pathogenetic factor in Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Altered lymphocyte distribution in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Inflammation and Alzheimer's disease pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

The remedy may lie in ourselves: prospects for immune cell therapy in central nervous system protection and repair

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Elevated interleukin-6 secretion levels by mononuclear cells of Alzheimer's patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Complement activation by neurofibrillary tangles in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Senile dementia of Alzheimer's type (SDAT): reduced T8+-cell-mediated suppressor activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Decreased release of the angiogenic peptide vascular endothelial growth factor in Alzheimer's disease: recovering effect with insulin and DHEA sulfate

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Circulating biomarkers of cognitive decline and dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Lymphocyte subset patterns and cytokine production in Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Decreased levels of intrathecal interleukin 1 receptor antagonist in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Intrathecal inflammation precedes development of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Combination of serum markers related to several mechanisms in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Transforming growth factor-beta 1 is in plaques in Alzheimer and Down pathologies.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Reduced number and altered morphology of microglial cells in colony stimulating factor-1-deficient osteopetrotic op/op mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Immunology and immunotherapy of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Inflammation in neurodegenerative disease--a double-edged sword

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Intracerebroventricular injection of interleukin-1 stimulates the release of high levels of interleukin-6 and interleukin-1 receptor antagonist into peripheral blood in the primate.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Immune reactions associated with cerebral amyloid angiopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2982011-3

7 January 2021

10.1016/S0074-7742(07)82011-3

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17678963